clp290 (MedChemExpress)
Structured Review

Clp290, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/k-252a/CLP290/pmc12905008-59-9-12
Average 94 stars, based on 6 article reviews
Images
1) Product Images from "KCC2 Dysfunction Mediated by Microglial BDNF / TrkB Signaling Exacerbates Early Post‐Stroke Seizure Susceptibility"
Article Title: KCC2 Dysfunction Mediated by Microglial BDNF / TrkB Signaling Exacerbates Early Post‐Stroke Seizure Susceptibility
Journal: CNS Neuroscience & Therapeutics
doi: 10.1002/cns.70795
Figure Legend Snippet: CLP290 inhibition of KCC2 expression downregulation reduces epilepsy susceptibility after MCAO‐R. (A, B) Western blot quantification of mKCC2 relative to GAPDH (A) and NeuN (B) in whole hippocampal tissue (Sham: N = 4, MCAO‐R: N = 7, MCAO‐ R + CLP290: N = 7). CLP290 attenuated the downregulation of mKCC2 in surviving neurons. (C, D) Proportions of mice at each seizure level in each group at the initial PTZ dose of 40 mg/kg (C) and cumulative 50 mg/kg PTZ (D). (E) Proportion of mice with seizure Racine IV‐V at 40, 50, 60, and 70 mg/kg cumulative dose of PTZ. CLP290 pretreatment significantly reduced the proportion of MCAO‐R mice with seizure Racine IV‐V at 40 mg/kg, 50 mg/kg, and 60 mg/kg PTZ doses. (F) Mean Racine seizure scores at cumulative PTZ doses of 40, 50, 60, and 70 mg/kg. CLP290 pretreatment significantly reduced the mean seizure scores in MCAO‐R mice. (G) Cumulative PTZ dose required to reach Racine IV–V seizures in each group. CLP290 pretreatment significantly increased the cumulative dose of PTZ associated with causing seizures to Racine IV‐V (Sham: N = 10, MCAO‐R: N = 13, MCAO‐ R + CLP290: N = 10). (H) Simplified schematic summarizing that CLP290, acting downstream on KCC2, restores KCC2 function after MCAO‐R, thereby normalizing E GABA , reducing neuronal hyperexcitability, and ultimately lowering seizure susceptibility. * p < 0.05, ** p < 0.01, and *** p < 0.001 compared to the Sham group; # p < 0.05 and ## p < 0.01 compared to the MCAO‐R group.
Techniques Used: Inhibition, Expressing, Western Blot
Related Articles
Saline:Article Title: Combined use of CLP290 and bumetanide alleviates neuropathic pain and its mechanism after spinal cord injury in rats. Article Snippet: .. The Article Title: Combined use of CLP290 and bumetanide alleviates neuropathic pain and its mechanism after spinal cord injury in rats Article Snippet: .. The Article Title: Combined use of CLP290 and bumetanide alleviates neuropathic pain and its mechanism after spinal cord injury in rats. Article Snippet: The KCC2 agonist CLP290 (HY- 103023, MCE) was dissolved in a solution containing 50% PEG300 + 50% saline at a concentration of 50 mg/kg and administered intragastrically. .. The NKCC1 inhibitor bumetanide (HY- 17468, MCE) was prepared in 10 mg/mL saline solution containing 0.25% NaOH and administered intraperitoneally at a concentration of 30 mg/kg.29 The selection of the administration concentrations of Concentration Assay:Article Title: Combined use of CLP290 and bumetanide alleviates neuropathic pain and its mechanism after spinal cord injury in rats. Article Snippet: .. The Article Title: Combined use of CLP290 and bumetanide alleviates neuropathic pain and its mechanism after spinal cord injury in rats Article Snippet: .. The Article Title: Combined use of CLP290 and bumetanide alleviates neuropathic pain and its mechanism after spinal cord injury in rats. Article Snippet: The KCC2 agonist CLP290 (HY- 103023, MCE) was dissolved in a solution containing 50% PEG300 + 50% saline at a concentration of 50 mg/kg and administered intragastrically. .. The NKCC1 inhibitor bumetanide (HY- 17468, MCE) was prepared in 10 mg/mL saline solution containing 0.25% NaOH and administered intraperitoneally at a concentration of 30 mg/kg.29 The selection of the administration concentrations of Injection:Article Title: Nociceptor-localized KCC2 suppresses brachial plexus avulsion-induced neuropathic pain and related central sensitization. Article Snippet: Mice were allowed to recover for 1 w before following BPA modeling, behavioral analysis and DRG patch-clamp recording. rLV (synthetized by BrainVTA, Wuhan, China) carried KCC2 overexpression RNA (rLV-EF1α-KCC2-PGK-mcherryWPRE, rLV-OE group) and control rLV (rLV-EF1αmcherry-WPRE, rLV-Ctrl group) were used in this study protocol. .. Article Title: Nociceptor-localized KCC2 suppresses brachial plexus avulsion-induced neuropathic pain and related central sensitization Article Snippet: Mice were allowed to recover for 1 w before following BPA modeling, behavioral analysis and DRG patch-clamp recording. rLV (synthetized by BrainVTA, Wuhan, China) carried KCC2 overexpression RNA (rLV-EF1α-KCC2-PGK-mcherry-WPRE, rLV-OE group) and control rLV (rLV-EF1α-mcherry-WPRE, rLV-Ctrl group) were used in this study protocol. .. Control:Article Title: Nociceptor-localized KCC2 suppresses brachial plexus avulsion-induced neuropathic pain and related central sensitization. Article Snippet: Mice were allowed to recover for 1 w before following BPA modeling, behavioral analysis and DRG patch-clamp recording. rLV (synthetized by BrainVTA, Wuhan, China) carried KCC2 overexpression RNA (rLV-EF1α-KCC2-PGK-mcherryWPRE, rLV-OE group) and control rLV (rLV-EF1αmcherry-WPRE, rLV-Ctrl group) were used in this study protocol. .. Article Title: Nociceptor-localized KCC2 suppresses brachial plexus avulsion-induced neuropathic pain and related central sensitization Article Snippet: Mice were allowed to recover for 1 w before following BPA modeling, behavioral analysis and DRG patch-clamp recording. rLV (synthetized by BrainVTA, Wuhan, China) carried KCC2 overexpression RNA (rLV-EF1α-KCC2-PGK-mcherry-WPRE, rLV-OE group) and control rLV (rLV-EF1α-mcherry-WPRE, rLV-Ctrl group) were used in this study protocol. .. Article Title: Combined use of CLP290 and bumetanide alleviates neuropathic pain and its mechanism after spinal cord injury in rats. Article Snippet: The KCC2 agonist CLP290 (HY- 103023, MCE) was dissolved in a solution containing 50% PEG300 + 50% saline at a concentration of 50 mg/kg and administered intragastrically. .. The NKCC1 inhibitor bumetanide (HY- 17468, MCE) was prepared in 10 mg/mL saline solution containing 0.25% NaOH and administered intraperitoneally at a concentration of 30 mg/kg.29 The selection of the administration concentrations of other:Article Title: The WNK-OXSR1 osmosensing pathway mediates intestinal regeneration via Hippo-YAP signaling Article Snippet: Selection:Article Title: Combined use of CLP290 and bumetanide alleviates neuropathic pain and its mechanism after spinal cord injury in rats. Article Snippet: The KCC2 agonist CLP290 (HY- 103023, MCE) was dissolved in a solution containing 50% PEG300 + 50% saline at a concentration of 50 mg/kg and administered intragastrically. .. The NKCC1 inhibitor bumetanide (HY- 17468, MCE) was prepared in 10 mg/mL saline solution containing 0.25% NaOH and administered intraperitoneally at a concentration of 30 mg/kg.29 The selection of the administration concentrations of |
